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Introduction: The multidisciplinary treatment of non-small cell
lung cancer (NSCLC) has evolved, however, the impact on popu-
lation outcomes remains unclear. We examined the treatment and
survival pattern of patients with NSCLC over 20 years in Manitoba,
Canada.
Methods: All diagnoses of NSCLC from January 1, 1985, to
December 31, 2004, were extracted from the Manitoba Cancer
Registry. Treatment and survival data from the registry were com-
bined with administrative medical claims data. Patients were
grouped by treatment: surgery, chemotherapy, radiotherapy, or no
antineoplastic treatment. Adjuvant therapies were also examined.
Results: A total of 10,908 diagnoses of NSCLC were identified. The
proportion treated with surgery and radiotherapy declined over time
(annual percent change (APC) 0.28, p  0.009; APC 0.74, p 
0.0001, respectively), while more received chemotherapy or no
antineoplastic treatment (APC 0.57, p  0.0001 and 0.45, p 
0.0002, respectively). Postoperative radiotherapy use declined over
time (APC 0.87, p  0.0001). Median survival time improved for
the entire cohort after 1997 (0.46 months per annum (MPA), p 
0.04), and for those treated with primary surgery (post-1994: 2.85
MPA, p  0.05), chemotherapy (0.49 MPA, p  0.0001), and
concurrent chemoradiotherapy (0.30 MPA, p  0.03).
Conclusions: The survival of patients with NSCLC has improved
over time, driven by improvements in those treated initially with
surgery or chemotherapy. This occurred in the setting of fewer
surgical resections and increased chemotherapy use suggesting im-
proved patient selection. Coincident with these changes, multidisci-
plinary case conferences, clinical practice guidelines, and consoli-
dation of service may have contributed to these phenomena.
KeyWords: Non-small-cell lung carcinoma, Lung neoplasm, Treat-
ment, Survival, Population.
(J Thorac Oncol. 2009;4: 492–498)
The multidisciplinary treatment of lung cancers hasevolved over time.1 While lung cancer is the most com-
mon cause of cancer-specific mortality worldwide,2 the over-
all impact of treatment advances is unclear. Surgical resection
remains the standard treatment for early stage disease. Over
the past few decades there has been a steady decrease in
perioperative morbidity and mortality3 and improvements in
anesthetic care.4 Advances in diagnostic imaging, particularly
computed tomographic (CT) scanning and its combination
with positron emission tomography have assisted treatment
planning.5 The use of radiotherapy (RT) has changed signif-
icantly through computerized imaging and delivery tech-
niques such as three-dimensional conformal treatments, CT
simulation and treatment planning, stereotactic radiosurgery,
and intensity-modulated radiotherapy.6,7 Postoperative radio-
therapy (PORT) was used routinely in the past, however, it
remains controversial with evidence suggesting harm.8,9 RT
is now often used concurrently with chemotherapy (CRT) for
locally advanced disease, and in the palliative setting for
localized metastatic disease.1 Chemotherapy for non-small
cell lung cancer (NSCLC) has also evolved from a predom-
inantly palliative modality in the mid-1990s10 to now encom-
pass all stages of disease. There is evidence for improved
survival with adjuvant and palliative chemotherapy.11,12 Ev-
idence-based treatment guidelines exist for NSCLC, how-
ever, adherence remains poor.13 As a consequence, the impact
of these scientific advances on patient treatment and survival
at the population level remains unclear.
Approximately 600 patients are diagnosed with lung
cancer every year in Manitoba, a Canadian province with a
population of approximately 1.2 million.14 The treatment of
lung cancer in this province has occurred almost exclusively
at one university hospital since the mid-1990s. Multidisci-
plinary lung cancer case conferences also began at that time.
Overall surgical approaches have not changed significantly
since the 1980s. RT has used CT conformal treatment since
1995. Palliative chemotherapy has been in standard use since
1995, and adjuvant chemotherapy since 2005.For over 30
years, health services have been provided through an equal
access public payer system. These services have been re-
corded in administrative databases. All neoplastic diagnoses
have been recorded in the Manitoba Cancer Registry (MCR).
Using these population-based databases, we have tested the
hypothesis that survival for the NSCLC patient population in
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Manitoba from 1985 to 2004 has improved over time, corre-
sponding to changes in treatment.
PATIENTS AND METHODS
Databases
Since the early 1970s, physician contact and interven-
tion through billing tariffs, and International Classification of
Diseases (ICD) diagnostic codes have been coded in a Phy-
sician Claims database.15 In 1984, a personal health identifi-
cation number was added for every citizen of Manitoba. All
neoplastic diagnoses have been collected in the MCR through
a mandatory reporting system, since 1956. The MCR is 95 to
98% complete for cancer ascertainment.16
Cohort and Data Collection
All patients diagnosed with NSCLC from January 1,
1985, to December 31, 2004, were identified from the MCR
using the corresponding ICD-9 or ICD-10 codes and linked to
administrative data using the personal health identification
number. The following data were extracted: number of pri-
mary lung cancers, diagnosis date, date of birth, date of death
(censored at October 1, 2007), sex, treatment tariffs, and
treatment dates occurring on or following the date of diag-
nosis. Stage data were available for 1999 and 2004. The
diagnosis date recorded in the MCR is the date of the first
sample that pathologically confirmed NSCLC. Treatment
information for subjects with multiple primary tumors found
on the same pathology specimen (simultaneous diagnoses)
was recorded for the more advanced cancer. Multiple primary
lung cancers with different diagnosis dates (sequential diag-
noses) were considered as new events, with treatment infor-
mation recorded until the diagnosis date of the subsequent
primary lung cancer. University of Manitoba Research Ethics
Board approval was obtained with a waiver of informed
consent.
Analysis
The primary objectives were to: (A) quantify changes
in survival over time and (B) describe the pattern of treatment
with chemotherapy, RT, and surgery over time. Subjects were
grouped according to the year of diagnosis. To capture all
possible treatments, subjects were considered to have under-
gone treatment if the appropriate tariff code was found in
either the MCR or administrative database at any point on or
after the diagnosis date. The percentage of patients whose
initial treatment was chemotherapy, RT, or surgery was
calculated. Patients with no record of treatment in either
database were considered to have received no antineoplastic
treatment (NAT). Diagnoses made at autopsy or via death
certificate were included in the NAT group.
Further analysis was performed for additional treatment
modalities. Treatment was considered to be concurrent che-
motherapy and radiotherapy (CRT) if both treatments oc-
curred within 27 days of each other. Subsequent treatment
was considered to be adjuvant if it began between 28 and 90
days from the initial treatment date. Adjuvant treatment
groups were based on the treatment pair: surgery then che-
motherapy, surgery then RT, RT then surgery, RT then
chemotherapy, chemotherapy then surgery, chemotherapy
then RT, and CRT followed by surgery.
Patients with no date of death were censored for sur-
vival analysis at October 1, 2007. Median survival time
(MST) from the diagnosis date was calculated and stratified
by year of diagnosis and treatment modality. Agreement
between stage data and treatment group was assessed, with
the surgical group corresponding to Stage I and II disease.17
FIGURE 1. Demographic Data.
n  10,908. Number of diagnoses
( ), Mean age ( ), percent female
( ), and smoking prevalence ( ).
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Analysis was performed using SAS version 91 (SAS Insti-
tute, Cary, NC). Regression was performed using Joinpoint
Regression Program 3.0 (srab.cancer.gov/joinpoint).18 Exter-
nal funding was not obtained.
RESULTS
Demographics
A total of 10,908 cases of NSCLC were identified. Of
these, 389% (n  4243) were female. Simultaneous diag-
nosis occurred in 55 patients (0.5%), and sequential diag-
nosis in 154 (1.4%). Diagnosis of lung cancer via autopsy
or death certificate occurred in 151 cases (1.4%). Smoking
prevalence in Manitoba decreased over this time as shown in
Figure 1.19,20
The sex distribution increased from 30.7% being fe-
male in 1985 to 47.8% in 2004 (annual percent change [APC]
1.00, p  0.0001) (Figure 1). The percentage of female
patients increased in all groups except those treated with
upfront chemotherapy (surgery APC 1.1, 95% CI 0.8–1.4,
p  0.001; chemotherapy APC 0.2, 95% CI 0.5 to 0.9, p 
0.622; RT APC 0.9, 95% CI 0.6–1.1, p  0.001; NAT APC
1.1, 95% CI 0.8–1.3, p  0.001).
The mean age at diagnosis was 69.2 (standard deviation
(SD) 10.3) for men and 67.9 (SD 11.3) for woman (p 
0.0001) and increased by 0.18 years per annum for both sexes
(p 0.001). The mean age at diagnosis was 66.6 (SD 9.5), 62.0
(SD 10.4), 67.5 (SD 10.6), and 738 (SD 10.1) years in the
surgery, chemotherapy, RT, and NAT groups, respectively (p
0.001 for all between group comparisons). Mean age increased
in all groups (surgery 0.17 years per annum, 95% CI 0.12–0.22,
p  0.001; chemotherapy 0.30 years per annum, 95% CI
0.18–0.43, p  0.001; RT 0.19 years per annum, 95% CI
0.12–0.25, p  0.001; NAT 0.18 years per annum, 95%
CI 0.11–0.24, p  0001) (Figure 1).
Treatment Pattern
The percentage of patients treated with upfront surgery
decreased over time (APC 0.30, p  0.005) (Figure 2).
Primary RT also decreased from 40.7% in 1985 to 21.6% in
2004 (APC 0.73, p  0.001). Treatment with primary
chemotherapy increased from 2.6 to 9.5% (APC 0.58, p 
0.001). The NAT group increased during the same time from
26.7 to 37.7% (APC 0.44, p  0.001).
Treatment with concurrent CRT increased from 1.6%
of all patients receiving therapy in 1993 to 8.4% in 1998
(APC 1.73, p  0.003), decreasing to 6.2% in 2004 (APC
0.67, p  0.005) (Figure 3). Preoperative CRT increased
from 1.5% in 1985 to 8.0% in 1998 (APC 0.38, p  0.0001),
declining to 0% in 2004 (APC 0.9, p  0.0006). No
patients received preoperative chemotherapy or RT alone.
Adjuvant chemotherapy increased from 0% in 1985 to 5.2%
in 2004 (APC 0.16, p  0.0006). Adjuvant radiotherapy
FIGURE 2. Percentage treated by modality and
year of diagnosis. Modality: surgery ( ), chemo-
therapy ( ), radiotherapy ( ), no antineoplastic
treatment ( ).
FIGURE 3. Percentage of patients treated with
primary surgery, chemotherapy, or radiotherapy
in adjuvant treatment groups by year of diagno-
sis. Modalities: Surgery followed by adjuvant che-
motherapy ( ), Neo-adjuvant chemotherapy and
radiotherapy (CRT) then Surgery ( ), postopera-
tive radiotherapy (PORT) ( ), or CRT ( ).
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(PORT) decreased from 17.0% in 1985, to 3.2% in 2004
(APC 0.87, p  0.0001).
Agreement between treatment assignment and patho-
logic stage, as measured by the kappa statistic, was 0.75 for
1999 and 0.78 for 2004.
Survival
MST increased from 6.6 months in 1998 to 9.0 months
in 2004 (0.46 months per annum, p  004) (Figure 4).
Survival was unchanged from 1985 to 1997 (0.08 months
per annum, p  0.14). Similarly, the MST in those treated
with surgery before 1994 did not change (0.04 months per
annum, p 0.97), compared with those treated after; increas-
ing from 34.7 months in 1994 to 56.8 months in 2001 (2.85
months per annum, p  0.05) (Figure 5). For those treated
with surgery after 2001, MST was not reached at 34 to 70
months follow-up. Five year overall survival decreased from
43.5% in 1985 to 29.5% in 1990 (APC 2.70, p  0.13),
then increased to 48.0% in 2001 (APC 0.88, p  0.01). The
MST for patients treated with chemotherapy, increased from
8.1 months in 1985 to 9.8 months in 2004 (regression esti-
mate 2.4 months to 11.9 months, 0.49 months per annum, p
0.0001) (Figure 4). Patients treated with CRT had an increas-
ing MST (0.30 months per annum, p 0.03). No change was
seen in the MST of patients treated with RT or given NAT
(0.02 months per annum, p  0.42; 0.002 months per
annum, p  0.84, respectively).
DISCUSSION
The survival of patients diagnosed with NSCLC in our
population has improved over time. Patients treated surgi-
cally have had the most striking benefit despite fewer patients
undergoing surgery. The survival of patients receiving che-
motherapy is increasing, with a corresponding increase in the
use of this modality. In addition, the MST for patients treated
with CRT has increased. RT use as a primary modality has
declined, and the MST of patients receiving RT has not
changed. Finally, more patients are not receiving NAT.
Demographics
A significant increase in the proportion of female cases
was observed. This has been well described in the literature
corresponding to a later rise in smoking prevalence in fe-
males.2,21 The mean age of NSCLC patients in our population
has also steadily increased since 1985. This is expected given
the aging demographics of the population as a whole, and has
been previously demonstrated in NSCLC using Surveillance,
Epidemiology, and End Results data.22
Treatment Pattern
Our data demonstrate a decline in the proportion of
patients treated with primary surgical resection. Stage migra-
tion is one possible explanation whereby advances in staging
modalities, such as positron emission tomography scanning,
with increased sensitivity for metastatic disease would render
FIGURE 4. Scatter plot and linear spline regres-
sion of median survival by year of diagnosis.
FIGURE 5. Median survival of non-small cell lung
cancer (NSCLC) patients treated by modality. Mo-
dality: surgery ( ), chemotherapy ( ), radiother-
apy ( ), chemotherapy and radiotherapy (CRT)
( ) or no antineoplastic treatment ( ).
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more patients inoperable.23,24 Similarly, treatment selection
by physicians may have changed through individual or col-
lective experience at multidisciplinary case conferences. The
increased use of surgical resection following CRT until 1998,
and subsequent decline also reflect these phenomena. This
tri-modality approach remains controversial for locally ad-
vanced disease.25
Radiotherapy use as both a primary and adjuvant
(PORT) modality has declined in our population. For upfront
RT, the decrease may be due to patient selection and stage
migration as above. The discovery of widespread disease may
shift the treatment paradigm from localized RT to upfront
chemotherapy. The decline in PORT may correspond to an
increase in the use of adjuvant chemotherapy.9 It may also
reflect controversy in the literature, though we did not find a
specific decrease in the use of RT corresponding to the
publication of the PORT meta-analyses.8,26
In contrast, the use of systemic chemotherapy has
clearly risen. Mounting evidence of a survival benefit from
chemotherapy in the metastatic setting has likely contributed
to the increase.27,28 Although increasing, the rate of chemo-
therapy for metastatic NSCLC in our population remains less
than the 22 to 31% reported in Surveillance, Epidemiology,
and End Results analyses from the USA, and the 28%
reported from France.29–31 These studies generally report
total use of chemotherapy, whereas our study divided che-
motherapy based on the timing of its use. This discrepancy
may also relate to practice differences between Canada and
these countries. A Scottish population-based study reported
chemotherapy use in approximately 8% of NSCLC patients in
1995, which closely approximates our results.32 The French
data support our finding of increasing use of chemotherapy in
the metastatic setting over time.31 Despite the increasing
proportion of females with lung cancer, the proportion of
females receiving chemotherapy did not increase. This sug-
gests a decreasing proportion of females receiving chemo-
therapy over time in our cohort. Females have been shown to
be less likely than males to receive chemotherapy,30 however,
it remains unclear if this is a reflection of patient preference
or gender bias. The lower mean age of patients receiving
chemotherapy may be a reflection of comorbidity in older
patients, patient preference to forego treatment to preserve
quality of life, age bias, or a lack of evidence for benefit in the
elderly.30
The increasing use of chemotherapy in the adjuvant
setting is consistent with trends in the literature suggesting a
survival benefit prior to 1995.11 Recent data has established
adjuvant chemotherapy as standard treatment, which may
explain the continued rise in more recent years.33–35 Finally,
we found an increase in the use of CRT beginning in the
mid-1990s that may also correspond to established survival
gains in this area.36–39 The decrease seen from 1998 to 2004
again likely reflects stage migration and patient selection
because no specific changes in practice occurred at that time.
The proportion of patients not receiving NAT increased
in our population. Previous studies have reported similar rates
of no treatment.13,31,32 This increase is expected given the
stage migration and improved patient selection already de-
scribed. More patients would be found to have metastatic
disease, with a proportionate increase in those choosing to
have no therapy. Additionally, this may reflect the increasing
age and associated comorbidity of the population.29,40,41 An-
other consequence of advancing age may be a reluctance of
either the physician or patient to be referred for treatment.
Referral to an oncologist is a strong predictor of treatment,
and in turn is related to geographic location and treatment at
a teaching institution.42 Reduced rates of treatment for
NSCLC have also been associated with African-American
ethnicity, poor socioeconomic status, and marital status, how-
ever, these were not evaluated in our study.13,29,42–44
Survival
The improvement in survival for this population began
in the mid 1990s, corresponding to significant changes in
clinical practice. In 1996, surgical treatment moved from
community hospitals to one university hospital. This consol-
idated surgeons, medical oncologists, and radiation oncolo-
gists at one site and enabled a weekly multidisciplinary case
conference. Another major change was the development of
province-wide clinical practice guidelines for the manage-
ment of lung cancer in 1997. Treatment specific changes may
have also contributed to the improvements in survival.
A striking improvement was seen in the survival of
those treated with surgical resection. Technological improve-
ments in preoperative imaging, particularly improved CT
resolution, have likely played a major role in improving
patient selection and surgical planning. Improved imaging
has resulted in a more homogeneous population of stage I and
II surgical patients. Stage migration can improve survival as
the upstaged patient would have poorer survival than those
truly stage I and II.24 Similarly, the upstaged patient would
have a better prognosis than those with overtly advanced
disease. In addition, the shift of surgical service to a teaching
hospital corresponded to more thoracic surgeries being per-
formed by subspecialty trained thoracic surgeons (L. Tan,
University of Manitoba personal communication, 2007).
Treatment at university hospitals has previously been associ-
ated with improved surgical outcomes.45 Furthermore, the
decline in the use of PORT could have contributed to the
improvement in the surgery group. Improvements in surgical
technique through experience and training, and advances in
intra- and postoperative care have certainly contributed,
though the magnitude is difficult to measure.
Patients treated with chemotherapy were also found to
have improved survival in our population. Careful selection
of patients for chemotherapy and improvements in the treat-
ment of chemotherapy-related complications may have con-
tributed to our result, despite the modest progress reported in
the literature.1,46 Similarly, these factors may have benefited
those treated with CRT, who also had improved MST over
time. CRT is known to improve survival for patients with
stage III disease.35–38
For the RT group, the lack of improved survival is not
surprising given that clinical trials examining RT for meta-
static NSCLC have demonstrated only modest improvements
in survival in specific situations such as adjuvant therapy for
brain metastases and palliative thoracic radiation.46–49 We
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did not examine for these specific treatment indications, and
the effect of RT in our analysis may have been diluted by
other treatments.
Our study presents data from a stable population of
patients with access to a publicly funded health care system,
allowing us to examine the changes in treatment patterns with
the effectiveness of these interventions. Novel treatment
strategies are often assessed for efficacy in selected popula-
tions using clinical trials. Examining the outcome of patients
as these interventions are implemented into clinical practice
provides information about their effect in the real world. As
a population-based analysis, it avoids some of the criticisms
of clinical trials, namely referral and selection bias. Although
our data were collected prospectively, the questions and
analyses were generated retrospectively. Treatment groups
were defined a priori, the outcome was objective, and those
assessing outcome were unaware of our investigation,
thereby minimizing any potential for bias. We limited the
possibility of missing information by combining two com-
prehensive population-based databases to obtain a robust
analysis of treatment and outcome. Our data included tumor
stage at diagnosis for only 1999 and 2004, limiting our ability
to adjust for the effect of stage on prognosis over time. This
limitation likely did not change our results significantly
because surgical resection was very closely matched to early
stage disease for the years that staging information was
present. As well, it may be argued that stage at diagnosis
dictates the treatment approach. Treatment outside this para-
digm occurs in cases with atypical features, which may
explain the small discrepancy we observed between stage and
treatment. The improvement in median survival may have
been subject to lead-time bias. However, there was no pro-
gram of early diagnosis or screening for lung cancer in
Manitoba. If lead-time bias adequately explained our results
we would have observed an increase in the proportion of
patients undergoing surgery for limited disease, which we did
not. The use of crude survival as opposed to relative survival
as our outcome, allows for the possibility that some of the
improvement we observed may have been due to the im-
proved survival of the population as a whole over this time.
However, it is unlikely that this adequately explains our
results given the short median survival of lung cancer patients
as a whole, and the lack of improved survival in the NAT and
RT groups. As discussed above, increased imaging may also
result in stage migration through improved patient selection.
This is often a concern when examining a single treatment
modality over time.24 However, when considered for a pop-
ulation as we have done, it helps to explain true improve-
ments in survival as a result of selecting the most appropriate
treatment for all patients. Finally, diagnostic and surgical wait
times were not included in this analysis. It is unlikely that
these impacted patient outcome as no system-wide changes of
this nature occurred this has not been shown to influence
survival.50,51
In conclusion, we have observed an improvement in the
overall survival of NSCLC patients from 1985 to 2004. In
conjunction with this improvement, we have noted a decrease
in the use of surgical treatment and RT, with a concomitant
increase in the number treated with chemotherapy or NAT.
The advances seen may be principally related to improved
patient selection through progress in diagnostic imaging and
stage migration. The combination of clinical practice guide-
line institution, multidisciplinary case conferences, and con-
solidation of service at a teaching hospital have likely con-
tributed to this gain. This work raises a number of questions
regarding the treatment of this cancer. It remains unclear to
what extent the increasing age and proportion of females will
impact future treatment paradigms. Future work will be
required to describe the changes in imaging and ancillary
treatments over this time.
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